The alliance gives Agilis a base in Japan and a partnership with a fellow CNS specialist to support its development of AAV vectors and gene therapies.
The split gives uniQure full rights to AMT-060 but leaves it without a partner to cofund R&D as it closes in on the start of a pivotal trial.
Aerie Pharma—just months away from a possible approval for its lead glaucoma drug—is hoping to unlock the potential of a key pipeline compound with help from…
BeiGene is adding Medidata’s electronic patient-reported outcome solution to oncology clinical studies.
The outlay gives Lilly the rights to a drug designed to treat autoimmune diseases by boosting the number and activity of regulatory T cells.
Sarepta offers Exondys 51 outside of the U.S. through a managed access program run by Clinigen, as an EMA decision is expected next year.
Erytech Pharma has formed a collaboration with Canada’s Queen’s University to advance its drug against the metabolic disorder arginase-1 deficiency.
Celgene has bought itself a spot toward the back of the pack in the PD-1 inhibitor market.
Merck KGaA has taken its oncology collaboration with Cancer Research Technology to the next level.
It’s time again to call on you to nominate your Fierce 15 for 2017.